$ISPR
Ispire Technology Inc. Stock $ispr

$ispr Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-K Financial Statement

#000121390024082378 Filed on September 27, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2024
Revenue	$39.34M	$37.34M	$151.9M
YoY Change	-8.23%	14.45%	31.4%
Cost Of Revenue	$31.66M	$26.78M	$122.1M
YoY Change	-11.99%	2.99%	29.19%
Gross Profit	$7.674M	$10.56M	$29.78M
YoY Change	11.41%	59.44%	41.31%
Gross Profit Margin	19.51%	28.29%	19.61%
Selling, General & Admin	$12.94M	$13.92M	$43.68M
YoY Change	65.87%	129.84%	70.31%
% of Gross Profit	168.58%	131.74%	146.65%
Research & Development			$779.2K
YoY Change			433.14%
% of Gross Profit			2.62%
Depreciation & Amortization	$188.5K	$1.579M	$479.1K
YoY Change	547.45%	6024.9%	926.72%
% of Gross Profit	2.46%	14.95%	1.61%
Operating Expenses	$12.94M	$13.92M	$43.68M
YoY Change	65.87%	129.84%	70.31%
Operating Profit	-$5.263M	-$3.352M	-$13.89M
YoY Change	477.53%	-687.52%	204.09%
Interest Expense	$117.7K	$960.00	$279.7K
YoY Change	55.01%	-100.25%	-316.81%
% of Operating Profit
Other Income/Expense, Net	$124.6K	$108.6K	$408.4K
YoY Change	-388.44%	-332.41%	-243.71%
Pretax Income	-$5.138M	-$3.243M	-$13.49M
YoY Change	484.84%	-2511.36%	177.87%
Income Tax	$456.8K	$178.3K	$1.282M
% Of Pretax Income
Net Earnings	-$5.595M	-$3.421M	-$14.77M
YoY Change	307.02%	8278.96%	142.15%
Net Earnings / Revenue	-14.22%	-9.16%	-9.72%
Basic Earnings Per Share	-$0.10		-$0.27
Diluted Earnings Per Share	-$0.10	-$0.06	-$0.27
COMMON SHARES
Basic Shares Outstanding	56.64M shares	56.40M shares	54.81M shares
Diluted Shares Outstanding	56.60M shares		54.81M shares

Balance Sheet

Concept	2024 Q3	2024 Q2	2024
SHORT-TERM ASSETS
Cash & Short-Term Investments	$37.73M	$35.07M	$35.07M
YoY Change	8.18%	-29.05%	-29.05%
Cash & Equivalents	$37.73M	$35.07M
Short-Term Investments		$0.00	$0.00
Other Short-Term Assets	$1.431M	$1.400M	$1.400M
YoY Change	-16.79%	-58.56%	-56.93%
Inventory	$6.992M	$6.365M	$6.365M
Prepaid Expenses
Receivables	$62.36M	$59.73M	$59.73M
Other Receivables	$0.00	$488.1K	$0.00
Total Short-Term Assets	$108.5M	$102.6M	$102.6M
YoY Change	32.96%	20.94%	20.94%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.663M	$2.582M	$6.162M
YoY Change	67.25%	137.33%	19.65%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$10.17M	$10.25M	$12.25M
YoY Change
Other Assets	$291.7K	$284.1K	$284.1K
YoY Change	-95.71%	-95.17%	-61.21%
Total Long-Term Assets	$20.44M	$20.07M	$20.07M
YoY Change	200.86%	241.19%	241.19%
TOTAL ASSETS
Total Short-Term Assets	$108.5M	$102.6M	$102.6M
Total Long-Term Assets	$20.44M	$20.07M	$20.07M
Total Assets	$129.0M	$122.6M	$122.6M
YoY Change	45.86%	35.23%	35.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.342M	$3.780M	$70.83M
YoY Change	-91.43%	196.59%	33.7%
Accrued Expenses	$1.179M	$1.012M	$12.95M
YoY Change	6712.11%	2723.86%	1101.29%
Deferred Revenue	$2.246M	$2.218M
YoY Change	74.06%	124.38%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$96.37M	$85.99M	$85.99M
YoY Change	78.44%	53.66%	53.66%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.870M	$2.194M	$2.194M
YoY Change	-44.8%	-34.63%	-34.63%
Total Long-Term Liabilities	$1.870M	$2.194M	$2.194M
YoY Change	-44.8%	-34.63%	-34.63%
TOTAL LIABILITIES
Total Short-Term Liabilities	$96.37M	$85.99M	$85.99M
Total Long-Term Liabilities	$1.870M	$2.194M	$2.194M
Total Liabilities	$98.24M	$88.18M	$88.18M
YoY Change	71.16%	48.66%	48.66%
SHAREHOLDERS EQUITY
Retained Earnings	-$14.42M	-$8.825M
YoY Change	-422.37%	-250.91%
Common Stock	$5.664K	$5.647K
YoY Change	4.37%	4.15%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$30.71M	$34.46M	$34.46M
YoY Change
Total Liabilities & Shareholders Equity	$129.0M	$122.6M	$122.6M
YoY Change	45.86%	35.23%	35.23%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2024
OPERATING ACTIVITIES
Net Income	-$5.595M	-$3.421M	-$14.77M
YoY Change	307.02%	8278.96%	142.15%
Depreciation, Depletion And Amortization	$188.5K	$1.579M	$479.1K
YoY Change	547.45%	6024.9%	926.72%
Cash From Operating Activities	$3.610M	-$1.424M	-$18.30M
YoY Change	-128.03%	-85.52%	141.4%
INVESTING ACTIVITIES
Capital Expenditures	$268.8K	$958.3K	$1.970M
YoY Change	-49.58%	82.28%	92.99%
Acquisitions
YoY Change
Other Investing Activities		-$2.000M	$6.134M
YoY Change		-524.89%	-167.15%
Cash From Investing Activities	-$925.2K	-$2.958M	$2.990M
YoY Change	17.3%	5278.65%	-129.45%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		0.000	$10.08M
YoY Change		-100.0%	-161.32%
NET CHANGE
Cash From Operating Activities	$3.610M	-1.424M	-$18.30M
Cash From Investing Activities	-$925.2K	-2.958M	$2.990M
Cash From Financing Activities		0.000	$10.08M
Net Change In Cash	$2.685M	-4.382M	-$5.229M
YoY Change	-118.37%	-126.94%	-84.7%
FREE CASH FLOW
Cash From Operating Activities	$3.610M	-$1.424M	-$18.30M
Capital Expenditures	$268.8K	$958.3K	$1.970M
Free Cash Flow	$3.341M	-$2.382M	-$20.27M
YoY Change	-124.91%	-77.0%	135.65%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	us-gaap	Taxes Payable Current TaxesPayableCurrent		usd
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2024	dei	Document Type DocumentType	10-K
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2024	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024	dei	Document Transition Report DocumentTransitionReport	false
CY2024	dei	Entity File Number EntityFileNumber	001-41680
CY2024	dei	Entity Registrant Name EntityRegistrantName	Ispire Technology Inc.
CY2024	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	93-1869878
CY2024	dei	Entity Address Address Line1 EntityAddressAddressLine1	19700 Magellan Drive
CY2024	dei	Entity Address City Or Town EntityAddressCityOrTown	Los Angeles
CY2024	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2024	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	90502
CY2024	dei	City Area Code CityAreaCode	(310)
CY2024	dei	Local Phone Number LocalPhoneNumber	742-9975
CY2024	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2024	dei	Trading Symbol TradingSymbol	ISPR
CY2024	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	true
CY2024	dei	Document Fin Stmt Restatement Recovery Analysis Flag DocumentFinStmtRestatementRecoveryAnalysisFlag	true
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Public Float EntityPublicFloat	210844339	usd
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	56641041	shares
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024	dei	Auditor Firm AuditorFirmId	717
CY2024	dei	Auditor Name AuditorName	MSPC
CY2024	dei	Auditor Location AuditorLocation	New York
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	40300573	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35071294	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	24526262	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	59734765	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	7472108	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	6365394	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3378617	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1400152	usd
CY2023Q2	us-gaap	Other Investments OtherInvestments	9133707	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	84811267	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	102571605	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1088131	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2582457	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1375666	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4253732	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3579140	usd
CY2024Q2	ispr	Cost Method Investment CostMethodInvestment	2000000	usd
CY2024Q2	us-gaap	Equity Method Investments EquityMethodInvestments	10248048	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	242614	usd
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	284050	usd
CY2023Q2	us-gaap	Other Assets OtherAssets	5584477	usd
CY2024Q2	us-gaap	Other Assets OtherAssets	20069361	usd
CY2023Q2	us-gaap	Assets Assets	90395744	usd
CY2024Q2	us-gaap	Assets Assets	122640966	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1274391	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	3779723	usd
CY2023Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	988556	usd
CY2024Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2218166	usd
CY2023Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	281361	usd
CY2024Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	11738339	usd
CY2023Q2	us-gaap	Taxes Payable Current TaxesPayableCurrent	63853	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	837100	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1207832	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	55854759	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	85990532	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3071075	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2194094	usd
CY2023Q2	us-gaap	Liabilities Liabilities	58925834	usd
CY2024Q2	us-gaap	Liabilities Liabilities	88184626	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	140000000	shares
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	140000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54222420	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54222420	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	56470636	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	56470636	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	5422	usd
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	5647	usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	25685475	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	43217391	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	5942781	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8825041	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-163768	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	58343	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	31469910	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	34456340	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	90395744	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	122640966	usd
CY2023	us-gaap	Revenues Revenues	115605536	usd
CY2024	us-gaap	Revenues Revenues	151908691	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	94828472	usd
CY2024	us-gaap	Cost Of Revenue CostOfRevenue	122126245	usd
CY2023	us-gaap	Gross Profit GrossProfit	20777064	usd
CY2024	us-gaap	Gross Profit GrossProfit	29782446	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4416220	usd
CY2024	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6608724	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20835001	usd
CY2024	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	37067861	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	25251221	usd
CY2024	us-gaap	Operating Expenses OperatingExpenses	43676585	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-4474157	usd
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-13894139	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	195209	usd
CY2024	us-gaap	Investment Income Interest InvestmentIncomeInterest	365251	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-324225	usd
CY2024	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-70293	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-155150	usd
CY2024	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	113405	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-284166	usd
CY2024	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	408363	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4758323	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13485776	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1245303	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1282046	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-6003626	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-14767822	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	20896	usd
CY2024	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	222111	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5982730	usd
CY2024	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14545711	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50725814	shares
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54812900	shares
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	11766743	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-6003626	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	25685897	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	-20896	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	31469910	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-14767822	usd
CY2024	ispr	Stock Issued During Period Value New Issues Of Secondary Offering StockIssuedDuringPeriodValueNewIssuesOfSecondaryOffering	10785906	usd
CY2024	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1183996	usd
CY2024	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	5196286	usd
CY2024	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	365953	usd
CY2024	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	-222111	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	34456340	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-6003626	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-14767822	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	46662	usd
CY2024	us-gaap	Depreciation And Amortization DepreciationAndAmortization	505653	usd
CY2023	us-gaap	Provision For Other Credit Losses ProvisionForOtherCreditLosses	3332825	usd
CY2024	us-gaap	Provision For Other Credit Losses ProvisionForOtherCreditLosses	6015752	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1030104	usd
CY2024	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1211899	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	6380282	usd
CY2024	us-gaap	Asset Impairment Charges AssetImpairmentCharges	205594	usd
CY2024	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-117905	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	19579339	usd
CY2024	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	41299642	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-7108449	usd
CY2024	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-901120	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2598746	usd
CY2024	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1937029	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	10574989	usd
CY2024	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	17891667	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-690637	usd
CY2024	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	1248687	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	168179	usd
CY2024	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2456979	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1427398	usd
CY2024	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1043556	usd
CY2023	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-417260	usd
CY2024	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-63853	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8455798	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18302306	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1020768	usd
CY2024	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1969961	usd
CY2024	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1173302	usd
CY2023	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	9133707	usd
CY2024	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	9133707	usd
CY2024	ispr	Acquisition Of Cost Method Investment AcquisitionOfCostMethodInvestment	2000000	usd
CY2024	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	1000000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10154475	usd
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2990444	usd
CY2023	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	21735000	usd
CY2023	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	3475172	usd
CY2023	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	7969221	usd
CY2024	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	12300000	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	543153	usd
CY2024	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1514094	usd
CY2023	us-gaap	Payments Of Dividends PaymentsOfDividends	3362639	usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	37893062	usd
CY2024	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	703323	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-15569805	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10082583	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-34180078	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-5229279	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	74480651	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	40300573	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	40300573	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	35071294	usd
CY2023	ispr	Leased Assets Obtained In Exchange For Operating Lease Liabilities LeasedAssetsObtainedInExchangeForOperatingLeaseLiabilities	4988032	usd
CY2024	ispr	Leased Assets Obtained In Exchange For Operating Lease Liabilities LeasedAssetsObtainedInExchangeForOperatingLeaseLiabilities	537307	usd
CY2024	ispr	Unpaid Long Term Investment In Accrued Liabilities And Other Payables UnpaidLongTermInvestmentInAccruedLiabilitiesAndOtherPayables	9000000	usd
CY2024	ispr	Warrants Issued In Connection With Equity Method Investment WarrantsIssuedInConnectionWithEquityMethodInvestment	365953	usd
CY2024	ispr	Unpaid Intangible Assets In Accrued Liabilities And Other Payables UnpaidIntangibleAssetsInAccruedLiabilitiesAndOtherPayables	232382	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1663240	usd
CY2024	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1355110	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	587	usd
CY2024	us-gaap	Interest Paid Net InterestPaidNet	15229	usd
CY2024	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2022-06-13
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	874039	usd
CY2023Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	242182	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	4988032	usd
CY2023Q3	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	537307	usd
CY2024	ispr	Shipping And Handling Cost ShippingAndHandlingCost	298703	usd
CY2023Q3	us-gaap	Selling Expense SellingExpense	43444	usd
CY2023Q4	us-gaap	Selling Expense SellingExpense	123308	usd
	us-gaap	Selling Expense SellingExpense	166752	usd
CY2023Q2	us-gaap	Prepaid Rent PrepaidRent	489720	usd
CY2023	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	94977	usd
CY2023Q3	us-gaap	Prepaid Rent PrepaidRent	489720	usd
CY2023Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	33028	usd
CY2023Q4	us-gaap	Prepaid Rent PrepaidRent	428505	usd
CY2023Q4	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	30412	usd
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	63440	usd
CY2024Q1	us-gaap	Prepaid Rent PrepaidRent	428505	usd
CY2024Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	24628	usd
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	88068	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	242614	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4253732	usd
CY2023Q2	us-gaap	Other Assets OtherAssets	5584477	usd
CY2023Q2	us-gaap	Assets Assets	90395744	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	837100	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	55854759	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3071075	usd
CY2023Q2	us-gaap	Liabilities Liabilities	58925834	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	5942781	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	31469910	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	90395744	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	94828472	usd
CY2023	us-gaap	Gross Profit GrossProfit	20777064	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4416220	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20835001	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	25251221	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-4474157	usd
CY2023	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-4758323	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1245303	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-6003626	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5982730	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-6003626	usd
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1030104	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2598746	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1427398	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8455798	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-15569805	usd
CY2023	us-gaap	Noncash Or Part Noncash Acquisition Other Liabilities Assumed1 NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1	4988032	usd
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates include allowance for credit losses and revenue recognition. Actual results could differ from those estimates.</p>
CY2023	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	0	usd
CY2024	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	205594	usd
CY2023Q2	us-gaap	Other Investments OtherInvestments	9133707	usd
CY2023Q2	us-gaap	Investment Maturity Date InvestmentMaturityDate	2024-02-08
CY2023	ispr	Finite Lived Patent Gross FiniteLivedPatentGross	0	usd
CY2024	ispr	Finite Lived Patent Gross FiniteLivedPatentGross	1405684	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
CY2024	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	30018	usd
CY2024Q2	us-gaap	Percentage Of Interest Bearing Domestic Deposits To Deposits PercentageOfInterestBearingDomesticDepositsToDeposits	0.30	pure
CY2024Q2	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.70	pure
CY2023	us-gaap	Revenues Revenues	115605536	usd
CY2024	us-gaap	Revenues Revenues	151908691	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	146149	usd
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	779174	usd
CY2024	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3911817	shares
CY2024	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Concentration and risks</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Risks and Uncertainties</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company’s business, financial condition and results of operations may be negatively impacted by risks related to government regulations, natural disasters, extreme weather conditions, health epidemics and other catastrophic incidents, which could significantly disrupt the Company’s operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>E-cigarette regulation</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regulation regarding e-cigarettes varies across countries, from no regulation to a total ban. The legal status of e-cigarettes is currently pending in many countries. But as e-cigarettes have become more and more popular recently, many countries are considering imposing more stringent law and regulations to regulate this market. Changes in existing law and regulations and the imposition of new laws and regulations in countries and regions that our major customers are located in may adversely affect the Company’s business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Federal Food, Drug, and Cosmetic Act requires all Electronic Nicotine Delivery Systems (“ENDS”) product manufacturers that market products in the United States to submit Premarket Tobacco Product Applications (“PMTAs”) to the Food and Drug Administration (“FDA”). For ENDS products that were on the U.S. market on or before August 8, 2016, a PMTA was required to be submitted to the FDA before September 9, 2020; for ENDS products that were not on the U.S. market prior to August 8, 2016, and for which a PMTA was not filed before September 9, 2020, a PMTA premarket authorization issued by FDA is required before the subject product may enter the U.S. market. The Company has submitted a PMTA filing for one ENDS product, and, under apparent FDA policies, FDA will not enforce the premarket review requirements for that product pending review of its PMTA. However, even with submission of the PMTA application, the FDA may reject the Company’s application and may prevent the Company’s ENDS products from being sold in U.S., which will adversely affect the Company’s business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Amendments to the Prevent All Cigarette Trafficking (“PACT”) Act, which became law in 2021, extend the PACT Act to include e-cigarette and all vaping products, and place significant burdens on sellers of vaping products in the United States which may make it difficult to operate profitably in the United States. Because of tighter government regulations, the Company has stopped marketing tobacco vaping products in the United States, as the volume of sales from the one tobacco vaping product which the Company may sell in the United States does not justify the marketing and regulatory costs involved.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, cannabis vaping products are governed by state laws, which vary from state to state. Most states do not permit the adult recreational use of cannabis, and no states permit the sale of recreational cannabis products to minors. As a result of the reduced revenue to states resulting from the effects of the COVID 19 pandemic, states may seek to raise revenue by permitting and taxing the use of cannabis products. The Company cannot predict what action states will take or the nature and amount of taxes they may impose. However, to the extent the PACT Act applies to cannabis products that aerosolize liquids, it may be more difficult to sell our products in states that permit the sale of cannabis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">However, cannabis and its derivatives containing more than 0.3% delta-9 tetrahydrocannabinol on a dry weight basis remain Schedule I controlled substances under U.S. federal law, meaning that federal law generally prohibits their manufacture and distribution. United States federal law also deems it unlawful to sell, offer for sale, transport in interstate commerce, import, or export “drug paraphernalia,” which includes “any equipment, product, or material of any kind which is primarily intended or designed for use in manufacturing, compounding, converting, concealing, producing, processing, preparing, injecting, ingesting, inhaling, or otherwise introducing into the human body a controlled substance” the possession of which federal law prohibits, including Schedule I “marijuana.” Limited exemptions exist, most notably when state or local law authorizes these items’ manufacture, possession, or distribution.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The European Commission issued the Tobacco Products Directive (the “TPD”), which became effective on May 19, 2014, and became applicable in the European Union member states on May 20, 2016. The TPD regulates e-cigarettes on the packaging, labelling and ingredients of the products on the European Union market, the creation of smoke-free environments, tax measures and activities against illegal trade and anti-smoke campaigns. Member states of the European Union are required to ensure that advertisements for any tobacco related product are prohibited, and no promotion shall be made as to those devices with an intention to promote e-cigarettes. For the e-cigarettes released after May 20, 2016, TPD requires e-cigarette manufacturers to submit product sales applications to the regulatory market six months in advance, and ensure their products can meet the TPD requirements before they can be released. The Company has complied with TPD requirement for products sold in Europe.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The sale of cannabis vaping products is illegal in the European Union and the United Kingdom.<b><i> </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Customer and Supplier Concentration</span></i></p><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> (a) Customers</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the year ended June 30, 2023 and 2024, the Company’s major customers, who accounted for more than 10% of the Company’s consolidated revenue, were as follows: </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Major Customers</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">A</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">32</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">30</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) Suppliers</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the year ended June 30, 2023 and 2024, the Company’s suppliers, who accounted for more than 10% of the Company’s total purchases, were as follows:</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Major Suppliers</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B<sup>(1)</sup></span></td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">92</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">78</td><td style="width: 1%; text-align: left">%</td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td><td style="text-align: justify">Major supplier B is Shenzhen Yi Jia, a Chinese company that is 95% owned by the Company’s co-chief executive officer and principal stockholder. See Note 13.</td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><i><span style="text-decoration:underline">Credit Risk</span></i> <b><i> </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, accounts receivable and investment – other. The Company maintains its cash in financial institutions. To the extent that such deposits exceed the maximum insurance levels, they are uninsured.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of June 30, 2023 and 2024, the Company’s customers, whose accounts receivable balances accounted for more than 10% of the Company’s total accounts receivable, were as follows:</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">As of <br/> June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">As of <br/> June 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid">Customers</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">C</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">11</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-62; font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">D</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-63; font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">E</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-64; font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16</td><td style="text-align: left">%</td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents the percentage was below 10%.</span></td> </tr></table>
CY2024	ispr	Derivatives Percentage DerivativesPercentage	0.003	pure
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	40300573	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35071294	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	40300573	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35071294	usd
CY2023Q2	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	26025068	usd
CY2024Q2	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	65620003	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1498806	usd
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	5885238	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	24526262	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	59734765	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	3332825	usd
CY2024	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	6015752	usd
CY2023	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	usd
CY2024	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	1629320	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1498806	usd
CY2024	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	6015752	usd
CY2024	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	1629320	usd
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	5885238	usd
CY2023Q2	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	3209413	usd
CY2024Q2	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	206480	usd
CY2023Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	26974	usd
CY2024Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	696960	usd
CY2023Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	142230	usd
CY2024Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	488104	usd
CY2024Q2	ispr	Prepaid Provisional Tax PrepaidProvisionalTax	8608	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3378617	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1400152	usd
CY2023Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	518854	usd
CY2024Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	817329	usd
CY2023Q2	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	339155	usd
CY2024Q2	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	1466840	usd
CY2023Q2	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	309990	usd
CY2024Q2	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	817308	usd
CY2024Q2	us-gaap	Construction In Progress Gross ConstructionInProgressGross	36483	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1167999	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3137960	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	79868	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	555503	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1088131	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2582457	usd
CY2023	us-gaap	Depreciation Depreciation	46629	usd
CY2024	us-gaap	Depreciation Depreciation	479066	usd
CY2024Q2	ispr	Equity Method Investment Shares Purchased EquityMethodInvestmentSharesPurchased	1816928	shares
CY2024	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	9000000	usd
CY2024	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	9000000	usd
CY2024	us-gaap	Investment Income Net InvestmentIncomeNet	10000000	usd
CY2024	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	117905	usd
CY2023Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	988556	usd
CY2024Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2218166	usd
CY2023Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	988556	usd
CY2024	ispr	Contract Liabilities Recognized Related To Advanced Deposits ContractLiabilitiesRecognizedRelatedToAdvancedDeposits	26880112	usd
CY2024	ispr	Revenue Recognized In Current Period RevenueRecognizedInCurrentPeriod	25650502	usd
CY2024Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2218166	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4253732	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3579140	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	837100	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1207832	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3071075	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2194094	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	3908175	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	3401926	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1432330	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1395767	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	857144	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	80676	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	3765917	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	363991	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	3401926	usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1237868	usd
CY2024	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1522974	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y8M12D
CY2024Q2	ispr	Joint Venture Investment Payable Current JointVentureInvestmentPayableCurrent	9000000	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	148197	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	575115	usd
CY2023Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	97314	usd
CY2024Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	432863	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	35850	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1012353	usd
CY2024Q2	ispr	Reserve For Product Returns Current ReserveForProductReturnsCurrent	717058	usd
CY2024Q2	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	950	usd
CY2023Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	281361	usd
CY2024Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	11738339	usd
CY2024	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	2000000	hkd
CY2024	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.165	pure
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4758323	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13485776	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-999248	usd
CY2024	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-2832013	usd
CY2023	ispr	Income Tax Reconciliation Tax Permanent Differences IncomeTaxReconciliationTaxPermanentDifferences	40311	usd
CY2024	ispr	Income Tax Reconciliation Tax Permanent Differences IncomeTaxReconciliationTaxPermanentDifferences	77429	usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-370425	usd
CY2024	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-460014	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2574665	usd
CY2024	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4427175	usd
CY2024	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	69469	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1245303	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1282046	usd
CY2024Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	13029870	usd
CY2024Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	7006420	usd
CY2024Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	24310876	usd
CY2024Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	23740602	usd
CY2024Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	1013283	usd
CY2024	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	11850516	usd
CY2024	ispr	Additions To Valuation Allowance Amount AdditionsToValuationAllowanceAmount	7350072	usd
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3062787	usd
CY2024Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7006420	usd
CY2023Q2	ispr	Deferred Tax Assets Foreign Payables DeferredTaxAssetsForeignPayables	981956	usd
CY2024Q2	ispr	Deferred Tax Assets Foreign Payables DeferredTaxAssetsForeignPayables	1310900	usd
CY2023Q2	ispr	Deferred Tax Assets Accounts Receivable Impairment DeferredTaxAssetsAccountsReceivableImpairment	508980	usd
CY2024Q2	ispr	Deferred Tax Assets Accounts Receivable Impairment DeferredTaxAssetsAccountsReceivableImpairment	1541584	usd
CY2024Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1529346	usd
CY2024Q2	ispr	Lease Liabilities LeaseLiabilities	939195	usd
CY2024Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	702425	usd
CY2023Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	4553723	usd
CY2024Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	13029870	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4500444	usd
CY2024Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11850516	usd
CY2023Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	53279	usd
CY2024Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1179354	usd
CY2023Q2	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	53279	usd
CY2024Q2	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	347779	usd
CY2024Q2	ispr	Deferred Tax Assets Right Of Use Assets DeferredTaxAssetsRightOfUseAssets	831575	usd
CY2023Q2	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	53279	usd
CY2024Q2	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	1179354	usd
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1925780	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4500444	usd
CY2023	ispr	Additions To Valuation Allowance Amount AdditionsToValuationAllowanceAmount	2574664	usd
CY2024	ispr	Additions To Valuation Allowance Amount AdditionsToValuationAllowanceAmount	7350072	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4500444	usd
CY2024Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11850516	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.50	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.044	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2024	us-gaap	Stock Issued During Period Shares Period Increase Decrease StockIssuedDuringPeriodSharesPeriodIncreaseDecrease	20000	shares
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	200000	shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	0	usd
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	3607816	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P2Y9M18D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2024	us-gaap	Restricted Stock Expense RestrictedStockExpense	1588470	usd
CY2024	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6380282	usd
CY2024Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	17517993	usd
CY2024	ispr	Weighted Average Period WeightedAveragePeriod	P2Y10M24D
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	140000000	shares
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q2	ispr	Increase Of Share Capital IncreaseOfShareCapital	311	usd
CY2024	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	18259518	usd
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-6003626	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-14767822	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50725814	shares
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54812900	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2024	ispr	Sold Cost Percentage SoldCostPercentage	0.20	pure
CY2024	ispr	Purchase Cost Percentage PurchaseCostPercentage	0.05	pure
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	170562	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4503560	usd
CY2023Q3	us-gaap	Other Assets OtherAssets	6521864	usd
CY2023Q3	us-gaap	Assets Assets	88135263	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1108566	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	53907753	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	3087165	usd
CY2023Q3	us-gaap	Liabilities Liabilities	56994918	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	4601194	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	31140345	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	88135263	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	299261	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4208840	usd
CY2023Q4	us-gaap	Other Assets OtherAssets	7383285	usd
CY2023Q4	us-gaap	Assets Assets	90391053	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1143944	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	58424361	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2821010	usd
CY2023Q4	us-gaap	Liabilities Liabilities	61245371	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	609283	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	29145682	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	90391053	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	297474	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3891368	usd
CY2024Q1	us-gaap	Other Assets OtherAssets	9323438	usd
CY2024Q1	us-gaap	Assets Assets	107975975	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1173346	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	69640466	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2476865	usd
CY2024Q1	us-gaap	Liabilities Liabilities	72117331	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5315841	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	35858644	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	107975975	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	36019799	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	6844848	usd
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1025219	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6697874	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	7723093	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-878245	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-845542	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-496045	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1341587	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1297124	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2023Q4	us-gaap	Cost Of Revenue CostOfRevenue	35432663	usd
CY2023Q4	us-gaap	Gross Profit GrossProfit	6252898	usd
CY2023Q4	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1394407	usd
CY2023Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8778715	usd
CY2023Q4	us-gaap	Operating Expenses OperatingExpenses	10173122	usd
CY2023Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-3920224	usd
CY2023Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3639732	usd
CY2023Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-352180	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-3991912	usd
CY2023Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3877585	usd
	us-gaap	Cost Of Revenue CostOfRevenue	71452462	usd
	us-gaap	Gross Profit GrossProfit	13097746	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2419626	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15476589	usd
	us-gaap	Operating Expenses OperatingExpenses	17896215	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4798469	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4485274	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-848225	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5333499	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5174709	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10022488	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	11777248	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5655295	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5669638	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-255485	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-5925123	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5914335	usd
	us-gaap	Cost Of Revenue CostOfRevenue	95345545	usd
	us-gaap	Gross Profit GrossProfit	19219699	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4174386	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	25499077	usd
	us-gaap	Operating Expenses OperatingExpenses	29673463	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10453764	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10154912	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1103710	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11258622	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11089044	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1341587	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	287480	usd
CY2023Q3	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-249932	usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13122607	usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-703322	usd
CY2023Q3	ispr	Leased Assets Obtained In Exchange For Operating Lease Liabilities LeasedAssetsObtainedInExchangeForOperatingLeaseLiabilities	537307	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5333499	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	582201	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	138755	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-480529	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20232049	usd
	ispr	Leased Assets Obtained In Exchange For Operating Lease Liabilities LeasedAssetsObtainedInExchangeForOperatingLeaseLiabilities	537307	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11258622	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	899672	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1670907	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-795272	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16878126	usd
	ispr	Leased Assets Obtained In Exchange For Operating Lease Liabilities LeasedAssetsObtainedInExchangeForOperatingLeaseLiabilities	537307	usd
CY2024	ispr	Consulting Fee ConsultingFee	12500	usd
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Accelerated Vesting Number SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber	25000	shares
CY2024Q2	us-gaap	Other Investments OtherInvestments		usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet		usd
CY2023Q2	ispr	Cost Method Investment CostMethodInvestment		usd
CY2023Q2	us-gaap	Equity Method Investments EquityMethodInvestments		usd
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50725814	shares
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54812900	shares
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation		usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
CY2024	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments		usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments		usd
CY2023	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments		usd
CY2024	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2024	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering		usd
CY2024	us-gaap	Payments Of Dividends PaymentsOfDividends		usd
CY2023	ispr	Unpaid Long Term Investment In Accrued Liabilities And Other Payables UnpaidLongTermInvestmentInAccruedLiabilitiesAndOtherPayables		usd
CY2023	ispr	Warrants Issued In Connection With Equity Method Investment WarrantsIssuedInConnectionWithEquityMethodInvestment		usd
CY2023	ispr	Unpaid Intangible Assets In Accrued Liabilities And Other Payables UnpaidIntangibleAssetsInAccruedLiabilitiesAndOtherPayables		usd
CY2023	ispr	Principal Portion Of Lease Payments PrincipalPortionOfLeasePayments		usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount		shares
CY2023Q2	ispr	Prepaid Provisional Tax PrepaidProvisionalTax		usd
CY2023Q2	us-gaap	Construction In Progress Gross ConstructionInProgressGross		usd
CY2023Q2	ispr	Joint Venture Investment Payable Current JointVentureInvestmentPayableCurrent		usd
CY2023Q2	ispr	Reserve For Product Returns Current ReserveForProductReturnsCurrent		usd
CY2023Q2	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent		usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes		usd
CY2024	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes		usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments		usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost		usd
CY2023Q2	ispr	Lease Liabilities LeaseLiabilities		usd
CY2023Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther		usd
CY2023Q2	ispr	Deferred Tax Assets Right Of Use Assets DeferredTaxAssetsRightOfUseAssets		usd
CY2023Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2024Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense		usd
CY2023	us-gaap	Restricted Stock Expense RestrictedStockExpense		usd
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50725814	shares
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54812900	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
CY2023Q3	us-gaap	Diluted Earnings Per Share Pro Forma DilutedEarningsPerShareProForma	-0.02
CY2023Q3	ispr	Principal Portion Of Lease Payment PrincipalPortionOfLeasePayment		usd
CY2024	dei	Amendment Flag AmendmentFlag	false
CY2024	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0001948455
CY2024	ispr	Estimated Useful Life Description EstimatedUsefulLifeDescription	Shorter of the term of the lease or the estimated useful life of the assets

Files In Submission

Name	View Source	Status
0001213900-24-082378-index-headers.html	Edgar Link	pending
0001213900-24-082378-index.html	Edgar Link	pending
0001213900-24-082378.txt	Edgar Link	pending
0001213900-24-082378-xbrl.zip	Edgar Link	pending
ea0213350-10k_ispire.htm	Edgar Link	pending
ea021335001ex19-1_ispire.htm	Edgar Link	pending
ea021335001ex21-1_ispire.htm	Edgar Link	pending
ea021335001ex23-1_ispire.htm	Edgar Link	pending
ea021335001ex23-2_ispire.htm	Edgar Link	pending
ea021335001ex3-2_ispire.htm	Edgar Link	pending
ea021335001ex31-1_ispire.htm	Edgar Link	pending
ea021335001ex31-2_ispire.htm	Edgar Link	pending
ea0213350-10k_ispire_htm.xml	Edgar Link	completed
ea021335001ex32-1_ispire.htm	Edgar Link	pending
ea021335001ex4-1_ispire.htm	Edgar Link	pending
ea021335001ex97-1_ispire.htm	Edgar Link	pending
ex23-2_001.jpg	Edgar Link	pending
ex23-2_002.jpg	Edgar Link	pending
ex23-2_003.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
ispr-20240630.xsd	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ispr-20240630_cal.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
ispr-20240630_lab.xml	Edgar Link	unprocessable
ispr-20240630_def.xml	Edgar Link	unprocessable
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ispr-20240630_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ISPR
Ispire Technology Inc. Stock $ispr

2024 Q3 Form 10-K Financial Statement

#000121390024082378 Filed on September 27, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ISPR Ispire Technology Inc. Stock $ispr

2024 Q3 Form 10-K Financial Statement

#000121390024082378 Filed on September 27, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ISPR
Ispire Technology Inc. Stock $ispr